{"id":"NCT00228566","sponsor":"Cephalon","briefTitle":"Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome","officialTitle":"A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":null,"completion":"2006-07","firstPosted":"2005-09-29","resultsPosted":"2010-06-25","lastUpdate":"2013-07-19"},"enrollment":247,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Excessive Daytime Sleepiness","Narcolepsy","Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)"],"interventions":[{"type":"DRUG","name":"Armodafinil","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to assess patient reported outcomes with armodafinil treatment in terms of improvement in sleepiness, satisfaction with treatment, impact on ability to engage in life activities (ie, daily or work and family and/or social activities), and effects on fatigue. Clinician ratings on patient response to armodafinil treatment will also be assessed.","primaryOutcome":{"measure":"Number of Responders to the Patient Global Impression of Change (PGI-C) Ratings","timeFrame":"Weeks 4, 8, and 12, at 3 month intervals thereafter, and at a Final Visit (or last postbaseline observation). Evaluation continues until the Final Visit, which occurs when the product is commercially available or the marketing application is withdrawn.","effectByArm":[{"arm":"Armodafinil 150 to 250 mg/Day","deltaMin":241,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":13},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":246},"commonTop":["Headache","Nasopharyngitis","Nausea","Dry mouth","Upper respiratory tract infection"]}}